INT1154

From wiki-pain
Jump to: navigation, search
Context Info
Confidence 0.59
First Reported 1975
Last Reported 2008
Negated 2
Speculated 0
Reported most in Abstract
Documents 24
Total Number 24
Disease Relevance 9.30
Pain Relevance 15.32

This is a graph with borders and nodes. Maybe there is an Imagemap used so the nodes may be linking to some Pages.

signal transduction (CCK) extracellular space (CCK) extracellular region (CCK)
Anatomy Link Frequency
bowel 2
spinal 1
substantia nigra 1
plasma 1
esophageal sphincter 1
CCK (Homo sapiens)
Pain Link Frequency Relevance Heat
Cholecystokinin 106 100.00 Very High Very High Very High
Somatostatin 20 100.00 Very High Very High Very High
antagonist 19 100.00 Very High Very High Very High
Neuropeptide 18 100.00 Very High Very High Very High
Pain 18 100.00 Very High Very High Very High
substance P 10 100.00 Very High Very High Very High
Enkephalin 7 100.00 Very High Very High Very High
anticonvulsant 6 99.98 Very High Very High Very High
Morphine 13 99.96 Very High Very High Very High
corticosteroid 1 99.92 Very High Very High Very High
Disease Link Frequency Relevance Heat
Pancreatitis 18 99.88 Very High Very High Very High
Exocrine Pancreatic Insufficiency 3 99.88 Very High Very High Very High
Disease 28 99.78 Very High Very High Very High
Gallstones 3 99.54 Very High Very High Very High
Abdominal Pain 2 99.50 Very High Very High Very High
Malignant Tumors Of Salivary Glands 4 98.70 Very High Very High Very High
Dementia 1 98.52 Very High Very High Very High
Neuropathic Pain 5 98.24 Very High Very High Very High
Frailty 4 98.08 Very High Very High Very High
Pain 13 96.68 Very High Very High Very High

Sentences Mentioned In

Key: Protein Mutation Event Anatomy Negation Speculation Pain term Disease term
In five patients with mild to moderate impairment of exocrine function and pancreatic extract-responsive abdominal pain, there was a 39 +/- 11% decrease in basal CCK levels during extract therapy (p less than 0.05).
Negative_regulation (decrease) of CCK associated with abdominal pain and cholecystokinin
1) Confidence 0.59 Published 1985 Journal J. Lab. Clin. Med. Section Abstract Doc Link 3973464 Disease Relevance 0.41 Pain Relevance 0.69
Mechanism of cholecystokinin inhibition of lower esophageal sphincter pressure.
Negative_regulation (inhibition) of cholecystokinin in esophageal sphincter associated with cholecystokinin
2) Confidence 0.58 Published 1975 Journal Am. J. Physiol. Section Title Doc Link 165733 Disease Relevance 0 Pain Relevance 0.72
In rats, a postmortem delay of up to 8 hours did not affect SP, Met-Enk, PHI, or NPY and decreased SST, CCK, and VIP levels.
Neg (not) Negative_regulation (decreased) of CCK associated with somatostatin, cholecystokinin and substance p
3) Confidence 0.51 Published 1990 Journal Neurology Section Abstract Doc Link 2296359 Disease Relevance 0.17 Pain Relevance 0.76
In Huntington's disease, there is a decrease of the neuropeptides, substance P, enkephalins, and cholecystokinin in the striatonigral system, whereas in Parkinson's disease an increase of substance P is found in the substantia nigra.
Negative_regulation (decrease) of cholecystokinin in substantia nigra associated with substantia nigra, neuropeptide, enkephalin, disease, cholecystokinin and substance p
4) Confidence 0.46 Published 1983 Journal Clin. Neuropathol. Section Abstract Doc Link 6189657 Disease Relevance 0.28 Pain Relevance 0.68
To test the hypothesis, based on studies in healthy man and dog, that patients with impaired digestion due to severe pancreatic insufficiency have impaired postprandial cholecystokinin (CCK) secretion that can be improved by the addition of pancreatic enzymes, we have studied plasma CCK responses to a test meal with and without addition of pancreatic enzymes in 10 patients with pancreatic insufficiency and steatorrhea, in 8 patients with chronic pancreatitis without steatorrhea, and in 6 healthy subjects.
Negative_regulation (impaired) of cholecystokinin in plasma associated with steatorrhea, exocrine pancreatic insufficiency, chronic pancreatitis and cholecystokinin
5) Confidence 0.43 Published 1989 Journal Regul. Pept. Section Abstract Doc Link 2772268 Disease Relevance 0.72 Pain Relevance 0.37
Proglumide, an antagonist of cholecystokinin, has been shown to potentiate morphine analgesia in animal and human experimental pain models.
Negative_regulation (antagonist) of cholecystokinin associated with pain, antagonist, cholecystokinin, analgesia and morphine
6) Confidence 0.43 Published 1989 Journal Clin. Pharmacol. Ther. Section Abstract Doc Link 2659236 Disease Relevance 0.40 Pain Relevance 1.35
Results of this study indicate that pancreatic exocrine impairment is associated with elevated basal CCK levels, which may reflect a failure to provide feedback downmodulation of CCK release.
Negative_regulation (downmodulation) of CCK associated with cholecystokinin
7) Confidence 0.43 Published 1985 Journal J. Lab. Clin. Med. Section Abstract Doc Link 3973464 Disease Relevance 0.36 Pain Relevance 0.59
For CCK/CCK(A) receptors (CCK(A)-R), the evidence for their proposed involvement in diseases caused by impaired CCK release or CCK(A)-R mutations, pancreatic disorders (acute/chronic pancreatitis), gastrointestinal motility disorders (gallbladder disease, irritable bowel syndrome), pancreatic tumor growth and satiety disorders, is briefly reviewed.
Negative_regulation (impaired) of CCK in bowel associated with spastic colon, pancreatic cancer, gallbladder disease, disease, chronic pancreatitis and cholecystokinin
8) Confidence 0.43 Published 2002 Journal Pharmacol. Toxicol. Section Abstract Doc Link 12688377 Disease Relevance 0.84 Pain Relevance 0.61
For CCK/CCK(A) receptors (CCK(A)-R), the evidence for their proposed involvement in diseases caused by impaired CCK release or CCK(A)-R mutations, pancreatic disorders (acute/chronic pancreatitis), gastrointestinal motility disorders (gallbladder disease, irritable bowel syndrome), pancreatic tumor growth and satiety disorders, is briefly reviewed.
Negative_regulation (impaired) of CCK in bowel associated with spastic colon, pancreatic cancer, gallbladder disease, disease, chronic pancreatitis and cholecystokinin
9) Confidence 0.43 Published 2002 Journal Pharmacol. Toxicol. Section Abstract Doc Link 12688377 Disease Relevance 0.85 Pain Relevance 0.61
Novel mechanisms to stimulate GI motility and transit include blockade of cholecystokinin (CCK)A receptors and stimulation of motilin receptors.
Negative_regulation (blockade) of CCK associated with cholecystokinin
10) Confidence 0.42 Published 1999 Journal Can. J. Gastroenterol. Section Abstract Doc Link 10202210 Disease Relevance 0.27 Pain Relevance 0.80
We now report that systemic CI988, a specific antagonist of the cholecystokinin (CCK) type B receptor, effectively relieved the allodynia-like symptom, an effect that was reversed by the opioid receptor antagonist naloxone.
Negative_regulation (antagonist) of CCK associated with allodynia, antagonist, narcan, opioid receptor and cholecystokinin
11) Confidence 0.42 Published 1994 Journal Pain Section Abstract Doc Link 7912821 Disease Relevance 1.04 Pain Relevance 1.59
All responses to cholecystokinin-octapeptide and carbachol were abolished by dibutyryl-guanosine 3', 5'-cyclic monophosphate (5 x 10(-3) M) and atropine (10(-5) M), respectively (P < 0.0002 and P < 0.0002).
Negative_regulation (abolished) of cholecystokinin associated with cholecystokinin
12) Confidence 0.41 Published 1999 Journal Neurogastroenterol. Motil. Section Abstract Doc Link 10087534 Disease Relevance 0.08 Pain Relevance 0.55
However, also taking into account the altered gallbladder refilling noticed in SSc patients, this therapeutic option should be considered with caution, since the long-acting octreotide formulation has been shown to greatly increase the risk of gallstone formation probably by suppression of endogenous cholecystokinin release [71].
Negative_regulation (suppression) of cholecystokinin associated with gallstones, systemic sclerosis and cholecystokinin
13) Confidence 0.41 Published 2008 Journal BMC Gastroenterol Section Body Doc Link PMC2276219 Disease Relevance 1.13 Pain Relevance 0.05
Cholecystokinin antianalgesia: safety cues abolish morphine analgesia.
Negative_regulation (abolish) of Cholecystokinin associated with cholecystokinin, analgesia and morphine
14) Confidence 0.41 Published 1992 Journal Science Section Title Doc Link 1589765 Disease Relevance 0 Pain Relevance 1.23
While CCK appears to be a negative regulator of gastric acid secretion and postprandial release of gastrin in the normal human gastrointestinal tract, its impact on the pathogenesis of acid hypersecretion in Helicobacter pylori-infected individuals remains uncertain.
Negative_regulation (regulator) of CCK associated with ulcers and cholecystokinin
15) Confidence 0.40 Published 2002 Journal Pharmacol. Toxicol. Section Abstract Doc Link 12688378 Disease Relevance 0.09 Pain Relevance 0.43
INTRODUCTION: Cholecystokinin (CCK)-receptor antagonists have been found to markedly reduce the severity of pancreatitis and improve survival in experimental animal models of acute pancreatitis.
Negative_regulation (reduce) of CCK associated with antagonist, pancreatitis and cholecystokinin
16) Confidence 0.39 Published 2002 Journal Pancreas Section Abstract Doc Link 12131781 Disease Relevance 0.27 Pain Relevance 0.51
The anticonvulsant potencies of CCK, TRH, and opioid peptides have been defined more clearly with these methods.
Negative_regulation (potencies) of CCK associated with anticonvulsant, opioid and cholecystokinin
17) Confidence 0.38 Published 1986 Journal Adv Neurol Section Abstract Doc Link 2871723 Disease Relevance 0.25 Pain Relevance 0.53
Naloxone further reduced food and water intake during high but not low dose CCK or saline.
Negative_regulation (reduced) of CCK associated with narcan
18) Confidence 0.37 Published 1991 Journal Z Gastroenterol Section Abstract Doc Link 1714670 Disease Relevance 0 Pain Relevance 0.37
It is concluded that loperamide inhibits basal and amino acid-stimulated gallbladder motility and intraduodenal output of bilirubin and amylase, despite an enhanced postprandial cholecystokinin release.
Negative_regulation (inhibits) of cholecystokinin associated with cholecystokinin
19) Confidence 0.33 Published 1997 Journal Hepatology Section Abstract Doc Link 9252131 Disease Relevance 0 Pain Relevance 0.17
Lipase secretion was stimulated by secretin alone with no additional effect of CCK-9.
Neg (no) Negative_regulation (effect) of CCK
20) Confidence 0.31 Published 1988 Journal Z Gastroenterol Section Abstract Doc Link 3245254 Disease Relevance 0.18 Pain Relevance 0.09

General Comments

This test has worked.

Personal tools
Namespaces

Variants
Actions
Navigation
Toolbox